-
Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery
Tuesday, December 15, 2020 - 12:11pm | 243Medtronic PLC (NYSE: MDT) is well-positioned for a COVID-19 recovery and has upside to the consensus estimates for fiscal 2022, according to Morgan Stanley. The Medtronic Analyst: David Lewis upgraded Medtronic from Equal-Weight to Overweight and raised the price target from $...
-
COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test
Thursday, August 27, 2020 - 4:27pm | 811Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test. Abbott's BinaxNOW could be transformative, Morgan Stanley analyst David Lewis said in a note. The test is bigger and better than...
-
Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'
Wednesday, July 15, 2020 - 10:58am | 201Edwards Lifesciences Corp (NYSE: EW) and Abbott Laboratories (NYSE: ABT)announced an agreement this week to settle their patent dispute. Notably, Edwards will pay Abbott $100 million in royalty expenses through 2024, according to Morgan Stanley. The Edwards Lifesciences Analyst: David...
-
Johnson & Johnson Says Independent Labs Found No Asbestos In Recalled Powder
Wednesday, October 30, 2019 - 9:50am | 642Johnson & Johnson (NYSE: JNJ) is slowly starting to breathe again — without fear of asbestos. Studies by two independent labs found no asbestos in the company’s recalled crates of Baby Powder or in the exact bottle that sparked initial regulatory concerns, the company announced late...
-
Analysts Constructive On Intuitive Surgical Following Solid Quarter
Friday, October 18, 2019 - 12:41pm | 397Intuitive Surgical, Inc. (NASDAQ: ISRG) shares are sharply higher Friday following strong quarterly results. The Analysts Morgan Stanley analyst David Lewis reiterated an Overweight rating and $620 price target for Intuitive Surgical. (See his track record here) Wells Fargo analyst Larry Biegelsen...
-
Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom
Wednesday, October 16, 2019 - 2:26pm | 680Johnson & Johnson (NYSE: JNJ) stock was on the rise Wednesday following better-than-expected third-quarter earnings and guidance, but analysts are mostly leery of boosting recommendations in light of a string of legal challenges the company faces. The Analysts Morgan Stanley’s...
-
Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement
Wednesday, October 2, 2019 - 3:06pm | 708Johnson & Johnson (NYSE: JNJ) announced a $20.4-million agreement Wednesday with the Ohio counties of Cuyahoga and Summit to settle an opioid lawsuit with the state, removing the company from federal multidistrict litigation. The Analysts Credit Suisse analyst Matt Miksic reiterated an...
-
Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive
Tuesday, August 27, 2019 - 1:03pm | 829The Cleveland County District Court in Oklahoma ordered Johnson & Johnson (NYSE: JNJ) and its Janssen unit to pay $572 million to settle a lawsuit relating to their opioid drugs. The Analysts Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with...
-
Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts
Friday, July 19, 2019 - 10:23am | 927Robotic surgical system manufacturer Intuitive Surgical, Inc. (NASDAQ: ISRG) reported above-consensus second-quarter results Thursday. The Analysts Canaccord Genuity analyst Jason Mills maintained a Buy rating on Intuitive Surgical and lifted the price target from $575 to $610. Stifel...
-
After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk
Wednesday, July 17, 2019 - 1:24pm | 569Johnson & Johnson (NYSE: JNJ) shares are down 2% since the company reported a second-quarter earnings beat on Tuesday morning. Johnson & Johnson reported a 42% increase in net profit in the quarter. Revenue of $20.56 billion was down 1.3% from a year ago but also topped consensus analyst...
-
Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind
Tuesday, June 25, 2019 - 3:56pm | 306Medtronic PLC (NYSE: MDT)’s announcement that it is commencing an offer for more than $4 billion in debt securities should help the company manage its tax headwind, according to Morgan Stanley. The Analyst David Lewis maintained an Equal-weight rating on Medtronic with a $100 price...
-
Johnson & Johnson Analysts Laud Accelerating Pharma Business
Thursday, May 16, 2019 - 10:20am | 596Pharma giant Johnson & Johnson (NYSE: JNJ) hosted a review of its pharmaceutical businesses Wednesday, and analysts came away largely impressed. The Analysts Morgan Stanley analyst David Lewis maintained an Equal-weight rating on Johnson & Johnson with a $145 price target. BMO...
-
Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative
Wednesday, April 17, 2019 - 10:55am | 603Johnson & Johnson (NYSE: JNJ) kickstarted the large-cap pharma earnings season Tuesday with forecast-beating first-quarter results. The company narrowed its full-year earnings per share guidance but maintained its sales outlook. The Analysts Morgan Stanley analyst David Lewis maintained an...
-
Analysts Unfazed By Intuitive Surgical's Higher Opex Guidance
Friday, January 25, 2019 - 12:20pm | 530Intuitive Surgical, Inc. (NASDAQ: ISRG) reported Thursday after the market close with higher fourth-quarter non-GAAP earnings per share — which fell short of expectations — and revenue that was slightly ahead of estimates. The Analysts Morgan Stanley analyst David Lewis...
-
Analysts Stand By Johnson & Johnson Despite Earnings Pullback
Wednesday, January 23, 2019 - 9:50am | 542Johnson & Johnson (NYSE: JNJ) is on the up after a post-earnings plunge earlier this week. The firm marginally beat guidance in the fourth quarter but issued lower-than-expected guidance. Still, it’s retained the confidence of some Street experts. The Rating Raymond James analyst Jayson...